InvestSMART

Spyre Therapeutics (NASDAQ: SYRE) - Share Price

Current share price for SYRE : $87.210 0.16 (0.18%)+

Currency: USD ($)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

SYRE General Information +

NASDAQ Code SYRE
Industry/Sector Biotechnology
Market Cap ($M) 7,668
SYRE Share Price $87.210
Day High $87.900
Day Low $85.960
Last Close $87.050
SYRE Share Price Movement $0.16 ( 0.18% )
Prices as at 3:44, 4 Sep 2026
+Security prices are at best end-of-day and are indicative only.

SYRE Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
n/a n/a ($31.21) 38.22% 2.62 n/a n/a -4.88

SYRE Calendar of Events

Created Date Changed Date Event
15 April 2025 15 April 2025 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.